Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients-Reference-Cited by-同舟云学术

Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients

Published:2020-01-19 Issue:6 Volume:107 Page:1334-1342
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Desai Rishi J.¹,Gopalakrishnan Chandrasekar¹,Dejene Sara¹,Sarpatwari Ameet S.¹,Levin Raisa¹,Dutcher Sarah K.²,Wang Zhong²,Wittayanukorn Sara²,Franklin Jessica M.¹,Gagne Joshua J.¹

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

2. Office of Research and Standards Office of Generic Drugs Center of Drug Evaluation and Research, Food and Drug Administration Silver Spring Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1743

Reference39 articles.

1. IMS Institute for Healthcare Informatics.The use of medicines in the United States: review of 2011.2011.

2. US Food and Drug Administration.Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. Accessed February 15 2018.

3. What are narrow therapeutic index drugs?

4. Deficiencies of the FDA in Evaluating Generic Formulations: Addressing Narrow Therapeutic Index Drugs

5. Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation;Drug Design, Development and Therapy;2024-05

2. Pharmacokinetics and Generic Drug Switching: A Regulator’s View;Clinical Pharmacokinetics;2020-06-17

3. Oral Anticoagulants and Precision Medicine: Something Old, Something New;Clinical Pharmacology & Therapeutics;2020-05-10